Clinical Trial Update: A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 [Phase 3]

View source ↗

Summary

Sarepta Therapeutics reports a Phase 3 trial of Bidridistrogene Xeboparvovec (SRP-9003) for limb-girdle muscular dystrophy type 2E/R4; the study is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type
• Limb-girdle Muscular Dystrophy Type 2e

Drugs mentioned

• Bidridistrogene Xeboparvovec (SRP-9003)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Limb-girdle Muscular Dystrophy | Phase 3 | Status: ACTIVE_NOT_RECRUITING